Sfoglia per Autore
The use of pegylated liposomal doxorubicin (PLD) in association with weekly paclitaxel as second line therapy in metastatic bladder carcinoma: final results
2010-01-01 Albanese, GV; Pizzo, T; Galvano, A; Piazza, D; Macaluso, S; Provenzano, S; Badalamenti, G; Intrivici, C; Fulfaro, F; Gebbia, N
Combined treatment with fulvestrant plus capecitabine in elderly advanced breast cancer (EABC): Three-year evaluation of efficacy and safety
2010-01-01 Carreca, i; Amelio, r; Bellomo, f; Galvano, a; Pernice, g; Piazza, d
Monoclonal antibodies in gastrointestinal cancers
2013-01-01 Bronte, G.; Cicero, G.; Cusenza, S.; Galvano, A.; Musso, E.; Rizzo, S.; Sortino, G.; Roselli, M.; Bazan, V.; Fiorentino, E.; Russo, A
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations
2013-01-01 Fanale, D; Iovanna, JL; Calvo, EL; Berthezene, P; Belleau, P; Dagorn, JC; Ancona, C; Catania, G; D'Alia, P; Galvano, A; Gulotta, E; Lo Dico, S; Passiglia, F; Bronte, G; Midiri, M; Lo Re, G; Cicero, G; Bazan, V; Russo, A.
Ramucirumab and its use in gastric cancer treatment
2014-01-01 Bronte, G.; Galvano, A.; Cicero, G.; Passiglia, F.; Rolfo, C.; Bazan, V.; Russo, A.
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS?
2015-01-01 Bronte, G.; Silvestris, N.; Castiglia, M.; Galvano, A.; Passiglia, F.; Sortino, G.; Cicero, G.; Rolfo, C.; Peeters, M.; Bazan, V.; Fanale, D.; Giordano, A.; Russo, A.
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario
2015-01-01 Bronte, G.; Sortino, G.; Passiglia, F.; Rizzo, S.; Lo Vullo, F.; Galvano, A.; Bazan, V.; Rolfo, C.; Russo, A.
Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: Systematic review and meta-analysis of randomized controlled trials
2015-01-01 Battaggia A.; Donzelli A.; Font M.; Molteni D.; Galvano A.
Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis
2015-01-01 Mancuso A.; Mazzola A.; Cabibbo G.; Perricone G.; Enea M.; Galvano A.; Zavaglia C.; Belli L.; Camma C.
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy
2015-01-01 Bronte, G.; Lo Vullo, F.; Pernice, G.; Galvano, A.; Fiorentino, E.; Cicero, G.; Bazan, V.; Rolfo, C.; Russo, A.
The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis
2016-01-01 Passiglia, F; Galvano, A; Rizzo, S; Listì, A; Barraco, N; Insalaco, L; Bronte, E; Alessi, I; Guarini, A; Terruso, L; Castellana, L; Perez, A; Massihnia, D; Di Piazza, F; Calò, V; Castiglia, M; Bazan, V; Russo, A
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway
2016-01-01 Massihnia, D.; Galvano, A.; Fanale, D.; Perez, A.; Castiglia, M.; Incorvaia, L.; Listì, A.; Rizzo, S.; Cicero, G.; Bazan, V.; Castorina, S.; Russo, A.
Cardiotoxic Effects of Anti-VEGFR Tyrosine Kinase Inhibitors
2016-01-01 Bronte, E.; Galvano, A.; Novo, G.; Russo, A.
Dietary restriction: could it be considered as speed bump on tumor progression road?
2016-01-01 Cangemi, A.; Fanale, D.; Rinaldi, G.; Bazan, V.; Galvano, A.; Perez, A.; Barraco, N.; Massihnia, D.; Castiglia, M.; Vieni, S.; Bronte, G.; Mirisola, M.; Russo, A.
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
2016-01-01 Bronte, G.; Incorvaia, L.; Rizzo, S.; Passiglia, F.; Galvano, A.; Rizzo, F.; Rolfo, C.; Fanale, D.; Listì, A.; Natoli, C.; Bazan, V.; Russo, A.
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard?
2016-01-01 Bronte, Giuseppe; Passiglia, Francesco; Galvano, Antonio; Russo, Antonio*
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus
2016-01-01 Cabibi, D.; Caruso, S.; Bazan, V.; Castiglia, M.; Bronte, G.; Ingrao, S.; Fanale, D.; Cangemi, A.; Calò, V.; Listì, A.; Incorvaia, L.; Galvano, A.; Pantuso, G.; Fiorentino, E.; Castorina, S.; Russo, A.
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis
2016-01-01 Passiglia, F.; Bronte, G.; Bazan, V.; Galvano, A.; Vincenzi, B.; Russo, A.
Nintedanib in NSCLC: Evidence to date and place in therapy
2016-01-01 Bronte, G.; Passiglia, F.; Galvano, A.; Barraco, N.; Listì, A.; Castiglia, M.; Rizzo, S.; Fiorentino, E.; Bazan, V.; Russo, A.
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis
2016-01-01 Passiglia, F.; Bronte, G.; Bazan, V.; Natoli, C.; Rizzo, S.; Galvano, A.; Listì, A.; Cicero, G.; Rolfo, C.; Santini, D.; Russo, A.
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile